Uterine Cervical Cancer Clinical Trial
Official title:
Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).
Papillomaviruses are responsible for almost all cervical cancers. In France, there are more than 3000 new cases of cervical cancer each year and nearly 1000 deaths. One of the ways to prevent this cancer is screening by PCR on cervical sample for which national coverage rate remains very insufficient (<60%). The invasive and uncomfortable nature of cervical sampling has been identified as a major obstacle to screening. In this context, an alternative sample, such as the first-void urine, seems to be judicious. Nevertheless, some studies have shown a lack of sensitivity of the HPV PCR test on urine. As underlined by the French National Authority for Health (HAS), this is mainly due to a lack of standardization of urine collection. In this study, the investigators therefore propose to evaluate the performance of the HPV PCR test on first-void urine using a standardized protocol. Through a questionnaire, they will also evaluate the acceptability of the first void urine collection device.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Recruiting |
NCT04857528 -
Detecting HPV DNA in Anal and Cervical Cancers
|
||
Completed |
NCT01755897 -
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients
|
N/A | |
Recruiting |
NCT01667211 -
Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01226264 -
Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence
|
N/A | |
Recruiting |
NCT03961191 -
DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study
|
||
Enrolling by invitation |
NCT01393470 -
Evaluation of Long-term HPV Vaccine Efficacy
|
N/A | |
Terminated |
NCT00421096 -
Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
|
Phase 2 | |
Terminated |
NCT01284348 -
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT03961178 -
A Cohort Study for the Following up of Conization
|
||
Terminated |
NCT02317302 -
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05824494 -
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
|
Phase 2 | |
Completed |
NCT00184093 -
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03960879 -
DNA Methylation for Screening Uterine Cervical Lesions
|
||
Recruiting |
NCT04886700 -
Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer
|
Phase 2 | |
Completed |
NCT02095119 -
A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05231993 -
Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening
|
N/A | |
Recruiting |
NCT02036164 -
Adjuvant Chemotherapy for Locally Advanced Cervical Cancer
|
Phase 3 | |
Recruiting |
NCT04974424 -
Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV
|